2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Deborah M. Stephens, DO, discusses the phase 3 ELEVATE-RR trial comparing the safety and efficacy of acalabrutinib with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Deborah M. Stephens, DO, director of the CLL and Lymphoma Program, Huntsman Cancer Institute, discusses the phase 3 ELEVATE-RR trial (NCT02477696) comparing the safety and efficacy of acalabrutinib (Calquence) with ibrutinib (Imbruvica) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).
Results from the study showed no difference in efficacy between the 2 agents with regard to progression-free survival, according to Stephens. However, acalabrutinib showed a more favorable toxicity profile compared with ibrutinib in these patients, Stephens adds.
Acalabrutinib is a feasible option for this population, and its favorable toxicity profile may result in increased utilization of the agent, Stephens concludes.